ATE239492T1 - Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen - Google Patents
Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungenInfo
- Publication number
- ATE239492T1 ATE239492T1 AT00905696T AT00905696T ATE239492T1 AT E239492 T1 ATE239492 T1 AT E239492T1 AT 00905696 T AT00905696 T AT 00905696T AT 00905696 T AT00905696 T AT 00905696T AT E239492 T1 ATE239492 T1 AT E239492T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- medication
- produce
- heart disease
- bpi protein
- Prior art date
Links
- 230000001684 chronic effect Effects 0.000 title abstract 2
- 208000019622 heart disease Diseases 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 208000020446 Cardiac disease Diseases 0.000 abstract 1
- 102000052586 bactericidal permeability increasing protein Human genes 0.000 abstract 1
- 108010032816 bactericidal permeability increasing protein Proteins 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A61K38/1751—Bactericidal/permeability-increasing protein [BPI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11673699P | 1999-01-22 | 1999-01-22 | |
| PCT/US2000/001515 WO2000043028A2 (en) | 1999-01-22 | 2000-01-21 | Method of treating chronic cardiac disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE239492T1 true ATE239492T1 (de) | 2003-05-15 |
Family
ID=22368911
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00905696T ATE239492T1 (de) | 1999-01-22 | 2000-01-21 | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US6509317B1 (https=) |
| EP (1) | EP1143996B1 (https=) |
| JP (2) | JP2002535282A (https=) |
| CN (1) | CN1353614A (https=) |
| AT (1) | ATE239492T1 (https=) |
| AU (1) | AU778001B2 (https=) |
| CA (1) | CA2359681A1 (https=) |
| DE (1) | DE60002552T2 (https=) |
| MX (1) | MXPA01007031A (https=) |
| NZ (1) | NZ513087A (https=) |
| WO (1) | WO2000043028A2 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004517865A (ja) | 2000-12-01 | 2004-06-17 | ゾーマ テクノロジー リミテッド | Ｂｐｉタンパク質産物またはｂｐｉインヒビターを使用する、周皮細胞増殖の調節 |
| US20110002893A1 (en) * | 2008-11-03 | 2011-01-06 | Ut-Battelle, Llc | Diagnosis and treatment of congenital heart defects using nell1 |
| US9974759B2 (en) * | 2013-05-31 | 2018-05-22 | Indiana University Research And Technology Corporation | Beta 2 adrenoceptor antagonists for treating orthostatic hypotension |
| GB201319621D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201319620D0 (en) | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5643875A (en) | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
| US5578568A (en) * | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
| US5646114A (en) * | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
| CN1236320A (zh) * | 1996-05-10 | 1999-11-24 | 爱克斯欧玛公司 | 杀菌的/增强通透性的蛋白质产物用于人脑膜炎球菌血症的治疗用途 |
-
2000
- 2000-01-21 DE DE60002552T patent/DE60002552T2/de not_active Expired - Fee Related
- 2000-01-21 CN CN00805115A patent/CN1353614A/zh active Pending
- 2000-01-21 MX MXPA01007031A patent/MXPA01007031A/es not_active IP Right Cessation
- 2000-01-21 CA CA002359681A patent/CA2359681A1/en not_active Abandoned
- 2000-01-21 JP JP2000594481A patent/JP2002535282A/ja active Pending
- 2000-01-21 EP EP00905696A patent/EP1143996B1/en not_active Expired - Lifetime
- 2000-01-21 WO PCT/US2000/001515 patent/WO2000043028A2/en not_active Ceased
- 2000-01-21 AU AU27341/00A patent/AU778001B2/en not_active Ceased
- 2000-01-21 NZ NZ513087A patent/NZ513087A/xx unknown
- 2000-01-21 US US09/488,979 patent/US6509317B1/en not_active Expired - Fee Related
- 2000-01-21 AT AT00905696T patent/ATE239492T1/de not_active IP Right Cessation
-
2003
- 2003-01-14 US US10/342,169 patent/US7045501B2/en not_active Expired - Fee Related
-
2006
- 2006-04-05 US US11/398,989 patent/US20060171937A1/en not_active Abandoned
-
2007
- 2007-01-19 JP JP2007010878A patent/JP2007126479A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000043028A9 (en) | 2001-09-20 |
| CA2359681A1 (en) | 2000-07-27 |
| NZ513087A (en) | 2003-02-28 |
| US20030216312A1 (en) | 2003-11-20 |
| DE60002552T2 (de) | 2004-02-26 |
| US20060171937A1 (en) | 2006-08-03 |
| JP2007126479A (ja) | 2007-05-24 |
| EP1143996A4 (de) | 2002-04-24 |
| JP2002535282A (ja) | 2002-10-22 |
| DE60002552D1 (de) | 2003-06-12 |
| AU778001B2 (en) | 2004-11-11 |
| AU2734100A (en) | 2000-08-07 |
| WO2000043028A2 (en) | 2000-07-27 |
| WO2000043028A3 (en) | 2000-11-30 |
| US6509317B1 (en) | 2003-01-21 |
| CN1353614A (zh) | 2002-06-12 |
| EP1143996A2 (en) | 2001-10-17 |
| US7045501B2 (en) | 2006-05-16 |
| MXPA01007031A (es) | 2004-08-12 |
| EP1143996B1 (en) | 2003-05-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69636343D1 (de) | Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen | |
| ATE355852T1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
| ATE240744T1 (de) | Verwendung von csf-1-inhibitoren | |
| DE69434431D1 (de) | Methoden zur behandlung von muskelerkrankungen und muskelstörungen | |
| ATE468137T1 (de) | Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten | |
| DE69533040D1 (de) | Medikamente zur vorbeugung oder behandlung von vaskulären hämorrhagien | |
| DE69631478D1 (de) | Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen | |
| ATE359087T1 (de) | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen | |
| ATE353645T1 (de) | Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia | |
| DE59508961D1 (de) | Verwendung von weihrauch zur behandlung der alzheimer-krankheit | |
| DE4394931T1 (de) | Verwendung von Norastemizol zur Behandlung von allergischen Erkrankungen | |
| DE60125563D1 (de) | Verfahren zur verwendung eines humanen il-17 verwandten polypeptids zur behandlung von krankheiten | |
| DE60218843D1 (de) | Verfahren zur identifizierung von mitteln zur behandlung von diabetes | |
| ATE289816T1 (de) | Verwendung von mirtazapine zur herstellung eines medikaments zur behandlung von schlafapnoen | |
| DE69233725D1 (de) | Verwendung von DNA oder RNA zur Herstellung eines Medikaments zur Behandlung von Tumoren | |
| DE69130679D1 (de) | Die herstellung von zusammensetzungen zur behandlung von krankheiten der zellproliferation | |
| ATE239492T1 (de) | Verwendung von einem bpi protein zur herstellung eines medikamentes zur behandlung von chronischen herzerkrankungen | |
| ATE217191T1 (de) | Verwendung von phanquinon zur behandlung von alzheimer's krankheit | |
| ATE192923T1 (de) | Verwendung von boswelliasäure zur behandlung von hirntumoren | |
| ATE298246T1 (de) | Aktiviertes protein c zur behandlung von pankreatitis | |
| DE60128911D1 (de) | Verwendung von l-threo-methylphenidat zur herstellung eines medikamentes zur behandlung von psychischen erkrankungen | |
| DE50100833D1 (de) | Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen | |
| ATE492285T1 (de) | Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis | |
| DE69720064D1 (de) | Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen | |
| EA200401295A1 (ru) | Статиновая терапия для усиления поддержания когнитивной функции |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |